Sun Pharma and AstraZeneca Partner for Hyperkalaemia Treatment in India

Sun Pharmaceutical Industries Ltd and AstraZeneca Pharma India Ltd have entered into a partnership to promote and distribute Sodium Zirconium Cyclosilicate (SZC) in India. This collaboration focuses on providing a treatment for Hyperkalaemia, a condition that affects patients with chronic kidney disease and heart failure. Under the agreement, AstraZeneca will market SZC under the brand name Lokelma®, while Sun Pharma will distribute it as Gimliand®.

The financial terms of the agreement have not been disclosed. However, AstraZeneca will retain the intellectual property rights to SZC and hold the marketing authorization and import license for the molecule. This strategic move is aimed at increasing the availability of SZC across India, leveraging the capabilities of both companies in the pharmaceutical sector.

Operationally, both companies will engage in the promotion, marketing, and distribution of SZC under their respective brand names. AstraZeneca will focus on maintaining the intellectual property and regulatory aspects, while Sun Pharma will utilize its extensive field force and market presence to ensure widespread distribution and access to the treatment.

The timeline for the implementation of this partnership has not been explicitly detailed in the filing. However, the agreement is expected to commence following the necessary regulatory approvals and market preparations by both companies.

The partnership involves two major pharmaceutical entities in India. AstraZeneca, a science-led biopharmaceutical company, will manage the intellectual property and regulatory compliance. Sun Pharma, recognized as the largest pharmaceutical company in India, will leverage its market leadership and distribution network to enhance the reach of SZC.

Hyperkalaemia is a significant health concern, particularly for patients with chronic kidney disease and heart failure. The condition is associated with elevated serum potassium levels, which can lead to serious health complications. The availability of SZC as a treatment option is crucial for managing this condition, and the partnership between Sun Pharma and AstraZeneca aims to address this need in the Indian market.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The company operates in over 100 countries and is committed to delivering innovative medicines in therapy areas such as oncology, cardiovascular, renal, and metabolism.

Sun Pharmaceutical Industries Ltd is the world’s leading specialty generics company with a strong presence in specialty, generics, and consumer healthcare products. As the largest pharmaceutical company in India, Sun Pharma is known for its high-growth global specialty portfolio and extensive market reach, providing trusted medicines in over 100 countries.